No abstract

Introduction: It has been estimated that the metabolic syndrome may predict cardiovascular disease and the occurrence of sudden death, independent of the presence of other cardiovascular risk factors. The aim of the present study was to assess the metabolic syndrome among Turkmen women in this area. Material and Methods:The present study consisted of 160 Turkmen women. Baseline data and prevalence of metabolic syndrome and the components of metabolic syndrome in Turkmen women were determined. Observations and Results:The prevalence of high levels of fasting glucose, low levels of high density lipoproteincholesterol, high triglyceride levels, high waist circumference and high blood pressure were shown to be 29.37%, 70.62%, 35.62%, 75% and 26.25%, respectively. It was shown that high waist circumference (75%) and Low HDL-cholesterol levels (70.62%) were the most frequent characteristics in comparison to other metabolic components. The prevalence of high waist circumference, high triglyceride levels, high levels of fasting glucose, high blood pressure and BMIs which were ≥25 were higher in subjects with metabolic syndrome (92.85%, 73.21%, 73.21%, 57.14% and 83.92%, respectively). Conclusion:Metabolic syndrome is more prevalent among Turkmen women. Our data has shown that the prevalence of abnormal waist circumference in this ethnic group was highest. The waist circumference can be used as a predictor for cardiovascular disease and coronary heart disease.

Purpose of the Study: Inflammatory processes in the brain play an important role in etiopathogenesis of Obsessive-Compulsive Disorder (OCD). Cyclooxygenase inhibitors such as celecoxib reduce the production of proinflammatory cytokines. This triple-blind study aimed to investigate the efficacy of the addition of Celecoxib to selective serotonin reuptake inhibitors in treating Obsessive–Compulsive Disorder (OCD) Ther Methods: Sixty patients who met the diagnostic and statistical manual of mental disorders criteria –fourth edition (DSM-IV) were recruited in the study for OCD screening by two psychiatrists to participate in the trial. The participants included 23 patients who received SSRIs and celecoxib (400 mg twice daily) and 22 patients in the control group that received SSRIs and placebo. At the beginning of the study, in weeks four, eight and 12, the patients were assessed by a psychiatrist using the Yale-Brown Obsessive Compulsive Scale (Y-BCOS). The Results: A significant difference was observed in the change of scores on the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS) in week 12 compared with the onset of the study in two groups (t:-8.976, df:38, P:0.001). There was a significant difference between two groups in obsession (F:49.19, df:1, P≤0.001) and compulsion (F:13.78, df:1, P:0.001), and in obsessive compulsive disorder (F:57.25, df:1, P≤0.001) which was higher in Celecoxib group. The Conclusion: This study showed that adjuvant treatment with celecoxib can treat symptoms of OCD under treatment with SSRIs.